Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI

The microflora-sparing properties of fidaxomicin were examined during the conduct of a randomized clinical trial comparing vancomycin 125 mg 4 times per day versus fidaxomicin 200 mg twice per day for 10 days as treatment of Clostridium difficile infection (CDI). Fecal samples were obtained from 89...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Louie, Thomas J., Cannon, Kris, Byrne, Brendan, Emery, Judy, Ward, Linda, Eyben, Melissa, Krulicki, Walter
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2012
Matèries:
Supplement Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3388020/
https://ncbi.nlm.nih.gov/pubmed/22752862
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/cis338
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars